- Home
- IMMX vs CNTB Comparison
IMMX vs CNTB Comparison
Compare IMMX & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- CNTB
- Stock Information
- Founded
- IMMX 2014
- CNTB 2012
- Country
- IMMX United States
- CNTB United States
- Employees
- IMMX N/A
- CNTB N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- CNTB Health Care
- Exchange
- IMMX Nasdaq
- CNTB Nasdaq
- Market Cap
- IMMX 61.1M
- CNTB 54.4M
- IPO Year
- IMMX 2021
- CNTB 2021
- Fundamental
- Price
- IMMX $2.65
- CNTB $1.53
- Analyst Decision
- IMMX Strong Buy
- CNTB Strong Buy
- Analyst Count
- IMMX 1
- CNTB 2
- Target Price
- IMMX $7.00
- CNTB $7.50
- AVG Volume (30 Days)
- IMMX 137.1K
- CNTB 156.2K
- Earning Date
- IMMX 08-11-2025
- CNTB 09-04-2025
- Dividend Yield
- IMMX N/A
- CNTB N/A
- EPS Growth
- IMMX N/A
- CNTB N/A
- EPS
- IMMX N/A
- CNTB N/A
- Revenue
- IMMX N/A
- CNTB $26,033,000.00
- Revenue This Year
- IMMX N/A
- CNTB N/A
- Revenue Next Year
- IMMX N/A
- CNTB N/A
- P/E Ratio
- IMMX N/A
- CNTB N/A
- Revenue Growth
- IMMX N/A
- CNTB N/A
- 52 Week Low
- IMMX $1.26
- CNTB $0.51
- 52 Week High
- IMMX $3.00
- CNTB $1.60
- Technical
- Relative Strength Index (RSI)
- IMMX 61.44
- CNTB 66.20
- Support Level
- IMMX $2.16
- CNTB $1.05
- Resistance Level
- IMMX $2.80
- CNTB $1.20
- Average True Range (ATR)
- IMMX 0.17
- CNTB 0.09
- MACD
- IMMX 0.04
- CNTB 0.01
- Stochastic Oscillator
- IMMX 80.00
- CNTB 82.76
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.